Wednesday, June 10, 2026

Patent intelligence · AR

AR 133055

DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1

granted A61K 39/ 395 A IA61P 35/ 00 A IA61P/3500
Status granted
Years to expiry 19
Applicant portfolio 25
Patent details — AR 133055
Jurisdiction
AR
Status
granted
Grant date
Aug 20, 2025
Expiration
Aug 15, 2045
Applicant
ABLYNX NV [BE]
CPC classes
A61K 39/ 395 A I, A61P 35/ 00 A I, A61P/3500
View on Google Patents ↗

Quick answer

AR 133055 (DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1) is held by ABLYNX NV [BE]. Status: granted. Granted Aug 20, 2025. Expires Aug 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ABLYNX NV [BE]
Grant date
Expiration
Claims
CPC classes
A61K 39/ 395 A I, A61P 35/ 00 A I, A61P/3500

More from ABLYNX NV [BE]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026078159

    AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT

    ABLYNX NV [BE] · Expires Apr 11, 2046

    granted
  2. WO 2026030375

    NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

    GENZYME CORP [US] · Expires Jan 31, 2046

    granted
  3. WO 2025262150

    MOLÉCULES DE RECRUTEMENT D'ANTICORPS

    ABLYNX NV [BE] · Expires Dec 21, 2045

    granted
  4. MX 2025007399

    PROTEIN-BASED CONJUGATION CARRIERS

    ABLYNX NV [BE] · Expires Jul 27, 2045

    granted
  5. WO 2025133166

    VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE

    ABLYNX NV [BE] · Expires Jun 21, 2045

    granted
  6. WO 2025133252

    DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5

    ABLYNX NV [BE] · Expires Jun 21, 2045

    granted
  7. WO 2025133253

    EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE

    ABLYNX NV [BE] · Expires Jun 21, 2045

    granted

Frequently asked questions

What is US patent 133055?

AR 133055 (DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1) is held by ABLYNX NV [BE]. Status: granted. Granted Aug 20, 2025. Expires Aug 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns AR 133055?

ABLYNX NV [BE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does AR 133055 expire?

Our index shows an expiration date of Aug 15, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.